PanCAN welcomes Jon Mahrt, Chief Executive Officer of Optum Rx and Chief Growth Officer of Optum to the Board of Directors. In this Q&A, Jon shares his personal connection to the cause, his passion ...

The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

A new PanCAN-authored paper uses feedback provided by patients with pancreatic cancer to identify trends in reporting pain.

Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and ...

We're the national organization providing support, resources, volunteer opportunities and hope for people fighting pancreatic cancer.

The U.S Food & Drug Administration has granted approval for a targeted therapy called CABOMETYX ® to treat pancreatic neuroendocrine tumors, also called PNET or PanNET.

Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and ...

Makes: 1 16 oz smoothie By: Tuesday Hoelscher, RDN Ingredients: 1/2 c Boost High Protein 1/2 c full fat Greek yogurt 2 tbsp chia seeds 1/2 c spinach 1/2 c mango 1 c blueberries 1/2 c orange juice ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit outlines the latest advances in pancreatic cancer and offers key insights from ASCO GI 2025.

The U.S. Food and Drug Administration has granted accelerated approval for a new drug targeting a tumor alteration called NRG1 gene fusion found in roughly 3% of patients with pancreatic ...

Before reading about the incredible impact you’ve made this year, hear PanCAN Founder Pamela Acosta Marquardt and more express their heartfelt gratitude for your 25 years of dedication to helping ...